Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 12/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 7/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 3/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.43 |
| ▸ | CSNK2A3 | Q8NEV1 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4829052 | 0.83 | CA12 (0.38) | LMNAMAPTKDM4EDRD2DRD4 | |
| SCHEMBL17490826 | 0.69 | DRD2 (0.46) | CSNK2A1MAPTKDM4EDRD2DRD4 | |
| SCHEMBL13955138 | 0.68 | MAPT (0.45) | MAPTKDM4EDRD2DRD4ATM | |
| SCHEMBL13954896 | 0.68 | DRD2 (0.44) | LMNATP53MAPTKDM4EDRD2 | |
| SCHEMBL8803539 | 0.68 | ATM (0.39) | LMNATP53MAPTDRD2DRD4 | |
| SCHEMBL9734836 | 0.68 | PIM1 (0.44) | PIM1PIM2CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL9970255 | 0.68 | GPR35 (0.51) | LMNAMAPTKDM4EDRD2DRD4 | |
| SCHEMBL9424948 | 0.68 | PIM1 (0.55) | PIM1PIM2CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL4830635 | 0.67 | GPR35 (0.50) | LMNAMAPTKDM4EDRD2DRD4 | |
| SCHEMBL4310530 | 0.66 | PIM1 (0.53) | PIM1PIM2CSNK2A1CSNK2A2CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080125455-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, Receptor ligands | VERNALIS RESEARCH LIMITED | 2008-05-29 | — | — | US | disclosed |
| US-20080114018-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED | 2008-05-15 | — | — | US | disclosed |
| US-20080090858-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED | 2008-04-17 | — | — | US | disclosed |
| US-7323473-B2 | Administering (S)-1-(2,3,7,8-tetrahydrofuro[2,3-g]indol-1-yl)-2-propylamine; serotonin receptor antagonists (5HT/5HT2C) for treatment of obesity | VERNALIS RESEARCH LIMITED (GB) | 2008-01-29 | — | — | US | disclosed |
| US-7323487-B2 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED (GB) | 2008-01-29 | — | — | US | disclosed |
| US-7323486-B2 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED (GB) | 2008-01-29 | — | — | US | disclosed |
| US-20070105889-A1 | Condensed indoline derivatives and their use as 5HT , in particular 5hHT2c, receptor ligands | VERNALIS RESEARCH LIMITED | 2007-05-10 | — | — | US | disclosed |
| US-20070099981-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED | 2007-05-03 | — | — | US | disclosed |
| US-20070099980-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED | 2007-05-03 | — | — | US | disclosed |
| US-7173056-B2 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED (GB) | 2007-02-06 | — | — | US | disclosed |
| US-7166632-B2 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| US-7166613-B2 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2c, receptor ligands | VERNALIS RESEARCH LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| US-6962939-B1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED (GB) | 2005-11-08 | — | — | US | disclosed |
| EP-1202964-B1 | CONDENSED INDOLINE DERIVATIVES AND THEIR USE AS 5HT, IN PARTICULAR 5HT2C, RECEPTOR LIGANDS | VERNALIS RES LTD (GB) | 2005-10-12 | — | — | EP | disclosed |
| US-20050197380-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED | 2005-09-08 | — | — | US | disclosed |
| US-20050192334-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | VERNALIS RESEARCH LIMITED | 2005-09-01 | — | — | US | disclosed |
| US-20050187282-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2c, receptor ligands | VERNALIS RESEARCH LIMITED | 2005-08-25 | — | — | US | disclosed |
| EP-1202964-A1 | CONDENSED INDOLINE DERIVATIVES AND THEIR USE AS 5HT, IN PARTICULAR 5HT2C, RECEPTOR LIGANDS | VERNALIS RESEARCH LIMITED (GB) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001012602-A1 | CONDENSED INDOLINE DERIVATIVES AND THEIR USE AS 5HT, IN PARTICULAR 5HT2C, RECEPTOR LIGANDS | VERNALIS RESEARCH LIMITED (GB) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090858-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | HTR2C, HTR2A, HTR1A | PIM1 3706/4885PIM2 3392/4885CSNK2A1 2835/4885 |
| US-20050197380-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | HTR2C, HTR2A, HTR1A | PIM1 3706/4885PIM2 3392/4885CSNK2A1 2835/4885 |
| US-20050192334-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | HTR2C, HTR2A, HTR1A | PIM1 3706/4885PIM2 3392/4885CSNK2A1 2835/4885 |
| US-20080125455-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, Receptor ligands | HTR2C, HTR2A, HTR1A | PIM1 3712/4885PIM2 3401/4885CSNK2A1 2837/4885 |
| US-20080114018-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | HTR2C, HTR2A, HTR1A | PIM1 3706/4885PIM2 3392/4885CSNK2A1 2835/4885 |
| US-20050187282-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2c, receptor ligands | HTR2C, HTR2A, HTR1A | PIM1 3706/4885PIM2 3392/4885CSNK2A1 2835/4885 |
| US-20070099980-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | HTR2C, HTR2A, HTR1A | PIM1 3706/4885PIM2 3392/4885CSNK2A1 2835/4885 |
| US-20070105889-A1 | Condensed indoline derivatives and their use as 5HT , in particular 5hHT2c, receptor ligands | HTR2C, HTR2A, HTR5A | PIM1 4022/4885PIM2 3665/4885CSNK2A1 2903/4885 |
| US-20070099981-A1 | Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands | HTR2C, HTR2A, HTR1A | PIM1 3706/4885PIM2 3392/4885CSNK2A1 2835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.